SEHK:2181Biotechs
Mabpharm (SEHK:2181) First Profitable Year Tests Bullish Earnings Growth Narrative
Mabpharm (SEHK:2181) has reported its FY 2025 first half results with revenue of C¥274.2 million and basic EPS of C¥0.000702, while trailing 12 month figures show revenue of C¥646.1 million and basic EPS of C¥0.01 as the business moves through its first year of profitability. Over the past reported periods, revenue has shifted from C¥108.5 million in 1H FY 2024 to C¥149.7 million in 2H FY 2024 and then to C¥274.2 million in 1H FY 2025, with net income moving from a loss of C¥97.6 million in...